129 related articles for article (PubMed ID: 25117168)
1. Delayed onset perforating folliculitis associated with sorafenib.
Batalla A; Menéndez L; Blay P; Curto JR
Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
[No Abstract] [Full Text] [Related]
2. Perforating folliculitis-like reaction related to sorafenib.
Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
[No Abstract] [Full Text] [Related]
3. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
4. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
[TBL] [Abstract][Full Text] [Related]
5. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
6. Sorafenib-induced eruptive melanocytic lesions.
Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
[No Abstract] [Full Text] [Related]
7. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
8. [Side effects of sorafenib and countermeasures].
Nakayama M; Arai Y; Nishimura K
Hinyokika Kiyo; 2012 Nov; 58(11):635-7. PubMed ID: 23254792
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
[No Abstract] [Full Text] [Related]
10. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
11. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
12. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
13. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
[No Abstract] [Full Text] [Related]
14. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
[No Abstract] [Full Text] [Related]
15. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
[No Abstract] [Full Text] [Related]
16. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
Konca Degertekin C; Coşkun U; Baloş Törüner F; Aktürk M; Demirci U
Endocrine; 2012 Dec; 42(3):756-7. PubMed ID: 22562706
[No Abstract] [Full Text] [Related]
17. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
20. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]